Michael DiFiore
Stock Analyst at Evercore ISI
(0.56)
# 4,314
Out of 5,099 analysts
10
Total ratings
40%
Success rate
-14.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael DiFiore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALT Altimmune | Reiterated: Buy | $25 → $17 | $2.04 | +733.33% | 2 | Sep 24, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $392 → $649 | $396.32 | +63.76% | 2 | May 7, 2026 | |
| VTVT vTv Therapeutics | Initiated Coverage: Buy | $44 | $23.55 | +86.84% | 1 | Mar 12, 2026 | |
| SKYE Skye Bioscience | Initiated Coverage: Buy | $10 | $1.22 | n/a | 1 | Aug 15, 2025 | |
| HALO Halozyme Therapeutics | Reiterated: Buy | $55 | $128.62 | n/a | 2 | May 15, 2025 | |
| ATRA Atara Biotherapeutics | Downgraded: Hold | n/a | $8.20 | n/a | 1 | Nov 9, 2023 | |
| CLYM Climb Bio | Initiated Coverage: Buy | n/a | $9.75 | n/a | 1 | Sep 8, 2021 |
Altimmune
Sep 24, 2026
Reiterated: Buy
Price Target: $25 → $17
Current: $2.04
Upside: +733.33%
Madrigal Pharmaceuticals
May 7, 2026
Reiterated: Buy
Price Target: $392 → $649
Current: $396.32
Upside: +63.76%
vTv Therapeutics
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $23.55
Upside: +86.84%
Skye Bioscience
Aug 15, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $1.22
Upside: n/a
Halozyme Therapeutics
May 15, 2025
Reiterated: Buy
Price Target: $55
Current: $128.62
Upside: n/a
Atara Biotherapeutics
Nov 9, 2023
Downgraded: Hold
Price Target: n/a
Current: $8.20
Upside: n/a
Climb Bio
Sep 8, 2021
Initiated Coverage: Buy
Price Target: n/a
Current: $9.75
Upside: n/a